Skip to main content

Akiko Chiba

Associate Professor of Surgery
Surgical Oncology

Overview


Dr. Akiko Chiba is an Associate Professor of Surgery at Duke University Medical Center and Associate Program Director of Duke Breast Surgery Fellowship Program. She is a breast surgical oncologist who cares for patients with breast cancer, benign breast diseases and those with an increased risk of breast cancer. Her clinical interests include young patients with breast cancer, genetic mutation carriers, and de-escalation of surgical treatment after neoadjuvant therapies. She is also studying the role of microbiome in breast cancer and how modulation of microbiome could be used to improve patient outcome. 

In addition to her role at Duke Cancer Institute, Dr. Chiba serve as an advisory board member of Breast and Gyn Oncology System of Excellence with National Oncology Program Office, Veterans Health Administration. This is a national program to improve care for breast and gynecologic cancer of veterans. She is also the lead physician for National Teleoncology High Risk Breast Cancer Clinic. On the national level, she serves on the Breast Committee for Alliance for Clinical Trials in Oncology, Co-Chair of Editorial Committee for Association of Women Surgeons, and Vice-Chair of Member Engagement Committee for American Society of Breast Surgeons.

Office Hours


Please contact via email or contact administrative staff at 919-681-9156 for availability.

Current Appointments & Affiliations


Associate Professor of Surgery · 2024 - Present Surgical Oncology, Surgery
Member of the Duke Cancer Institute · 2022 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study.

Journal Article Breast Cancer Res Treat · July 2025 BACKGROUND: Neoadjuvant therapies can result in pathologic complete response (pCR) in patients with breast cancer, which can be predictive of long-term outcomes. Patients with estrogen receptor positive (ER +) tumors may receive either neoadjuvant chemothe ... Full text Link to item Cite

High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old.

Journal Article Breast Cancer Res Treat · June 2025 BACKGROUND: The risk of developing breast cancer up to age 80 for women with BRCA1/2 mutations is approximately 69-72%. The risk estimates, however, become labile in the later years of life. Many older BRCA1/2 mutation carriers who have not developed breas ... Full text Link to item Cite

Short-term Patient-Reported Outcomes Following Bilateral Risk-Reducing Mastectomy for Patients at a High Risk for Breast Cancer: A Systematic Review.

Journal Article Ann Surg Oncol · April 2025 BACKGROUND: Bilateral risk-reducing mastectomies (RRMs) have been proven to decrease the risk of breast cancer in patients at high risk owing to family history or having pathogenic genetic mutations. However, few resources with consolidated data have detai ... Full text Link to item Cite
View All Publications

Education, Training & Certifications


St. George's University, School of Medicine (West Indies) · 2009 M.D.
The George Washington University · 2003 B.S.
OSZAR »